S&P 500   3,626.87 (-0.23%)
DOW   29,882.33 (-0.55%)
QQQ   295.98 (+0.51%)
AAPL   116.02 (+0.74%)
MSFT   213.51 (-0.16%)
FB   275.35 (-0.57%)
GOOGL   1,766.18 (+0.13%)
AMZN   3,172.43 (+1.74%)
TSLA   571.37 (+2.88%)
NVDA   529.63 (+2.18%)
BABA   275.92 (-1.44%)
CGC   26.99 (+0.07%)
GE   10.50 (+0.48%)
MU   63.42 (-0.83%)
AMD   87.09 (+2.37%)
T   28.92 (-1.06%)
NIO   53.12 (-0.73%)
F   9.07 (-4.02%)
ACB   8.81 (-4.55%)
NFLX   482.34 (-0.11%)
GILD   59.76 (-0.81%)
BA   219.00 (+0.23%)
DIS   148.86 (-1.74%)
S&P 500   3,626.87 (-0.23%)
DOW   29,882.33 (-0.55%)
QQQ   295.98 (+0.51%)
AAPL   116.02 (+0.74%)
MSFT   213.51 (-0.16%)
FB   275.35 (-0.57%)
GOOGL   1,766.18 (+0.13%)
AMZN   3,172.43 (+1.74%)
TSLA   571.37 (+2.88%)
NVDA   529.63 (+2.18%)
BABA   275.92 (-1.44%)
CGC   26.99 (+0.07%)
GE   10.50 (+0.48%)
MU   63.42 (-0.83%)
AMD   87.09 (+2.37%)
T   28.92 (-1.06%)
NIO   53.12 (-0.73%)
F   9.07 (-4.02%)
ACB   8.81 (-4.55%)
NFLX   482.34 (-0.11%)
GILD   59.76 (-0.81%)
BA   219.00 (+0.23%)
DIS   148.86 (-1.74%)
S&P 500   3,626.87 (-0.23%)
DOW   29,882.33 (-0.55%)
QQQ   295.98 (+0.51%)
AAPL   116.02 (+0.74%)
MSFT   213.51 (-0.16%)
FB   275.35 (-0.57%)
GOOGL   1,766.18 (+0.13%)
AMZN   3,172.43 (+1.74%)
TSLA   571.37 (+2.88%)
NVDA   529.63 (+2.18%)
BABA   275.92 (-1.44%)
CGC   26.99 (+0.07%)
GE   10.50 (+0.48%)
MU   63.42 (-0.83%)
AMD   87.09 (+2.37%)
T   28.92 (-1.06%)
NIO   53.12 (-0.73%)
F   9.07 (-4.02%)
ACB   8.81 (-4.55%)
NFLX   482.34 (-0.11%)
GILD   59.76 (-0.81%)
BA   219.00 (+0.23%)
DIS   148.86 (-1.74%)
S&P 500   3,626.87 (-0.23%)
DOW   29,882.33 (-0.55%)
QQQ   295.98 (+0.51%)
AAPL   116.02 (+0.74%)
MSFT   213.51 (-0.16%)
FB   275.35 (-0.57%)
GOOGL   1,766.18 (+0.13%)
AMZN   3,172.43 (+1.74%)
TSLA   571.37 (+2.88%)
NVDA   529.63 (+2.18%)
BABA   275.92 (-1.44%)
CGC   26.99 (+0.07%)
GE   10.50 (+0.48%)
MU   63.42 (-0.83%)
AMD   87.09 (+2.37%)
T   28.92 (-1.06%)
NIO   53.12 (-0.73%)
F   9.07 (-4.02%)
ACB   8.81 (-4.55%)
NFLX   482.34 (-0.11%)
GILD   59.76 (-0.81%)
BA   219.00 (+0.23%)
DIS   148.86 (-1.74%)
Log in
NASDAQ:XLRN

Acceleron Pharma Stock Forecast, Price & News

$114.40
+0.31 (+0.27 %)
(As of 11/25/2020 01:28 PM ET)
Add
Compare
Today's Range
$113.65
Now: $114.40
$116.93
50-Day Range
$102.36
MA: $112.51
$122.18
52-Week Range
$44.62
Now: $114.40
$124.01
Volume4,126 shs
Average Volume573,856 shs
Market Capitalization$6.89 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.59
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Read More
Acceleron Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XLRN
CUSIPN/A
Phone617-649-9200
Employees237

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$73.99 million
Book Value$8.47 per share

Profitability

Net Income$-124,860,000.00
Net Margins-157.84%

Miscellaneous

Market Cap$6.89 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$114.40
+0.31 (+0.27 %)
(As of 11/25/2020 01:28 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XLRN News and Ratings via Email

Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

How has Acceleron Pharma's stock price been impacted by COVID-19?

Acceleron Pharma's stock was trading at $84.39 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, XLRN shares have increased by 35.6% and is now trading at $114.40.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Acceleron Pharma?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 1 sell rating, 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Acceleron Pharma
.

What stocks does MarketBeat like better than Acceleron Pharma?

Wall Street analysts have given Acceleron Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Acceleron Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Acceleron Pharma's next earnings date?

Acceleron Pharma is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Acceleron Pharma
.

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc. (NASDAQ:XLRN) issued its quarterly earnings data on Tuesday, November, 10th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.05. The biopharmaceutical company earned $22.60 million during the quarter, compared to analyst estimates of $26.52 million. Acceleron Pharma had a negative return on equity of 31.62% and a negative net margin of 157.84%. The firm's revenue was up 438.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.86) earnings per share.
View Acceleron Pharma's earnings history
.

What price target have analysts set for XLRN?

13 analysts have issued twelve-month target prices for Acceleron Pharma's shares. Their forecasts range from $73.00 to $155.00. On average, they anticipate Acceleron Pharma's stock price to reach $126.92 in the next year. This suggests a possible upside of 10.9% from the stock's current price.
View analysts' price targets for Acceleron Pharma
.

Who are some of Acceleron Pharma's key competitors?

What other stocks do shareholders of Acceleron Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Intel (INTC), Pfizer (PFE), Corcept Therapeutics (CORT), Cisco Systems (CSCO) and Regeneron Pharmaceuticals (REGN).

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the following people:
  • Mr. Habib J. Dable, CEO, Pres & Director (Age 51, Pay $1.02M)
  • Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director Emeritus (Age 77, Pay $22.5k)
  • Mr. Kevin F. McLaughlin, Sr. VP, CFO & Treasurer (Age 64, Pay $603.93k)
  • Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 60, Pay $543.06k)
  • Mr. Sujay R. Kango, Exec. VP & Chief Commercial Officer (Age 56, Pay $595.54k)
  • Dr. Mark Ptashne, Co-Founder and Member of Scientific Advisory Board
  • Ms. Lisa Wyman, Sr. VP of Technical Operations
  • Mr. Todd James IRC, Sr. VP of Corp. Affairs & Investor Relations
  • Mr. Adam M. Veness Esq., Sr. VP, Gen. Counsel & Sec. (Age 34)
  • Mr. Matthew S. Fearer, Director of Corp. Communications (Age 54)

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Who are Acceleron Pharma's major shareholders?

Acceleron Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.75%), Alkeon Capital Management LLC (2.70%), State Street Corp (1.92%), Lord Abbett & CO. LLC (1.72%), Candriam Luxembourg S.C.A. (0.84%) and Charles Schwab Investment Management Inc. (0.60%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Ravindra Kumar, Sujay Kango, Terrence C Kearney and Thomas A Mccourt.
View institutional ownership trends for Acceleron Pharma
.

Which institutional investors are selling Acceleron Pharma stock?

XLRN stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Paloma Partners Management Co, Cubist Systematic Strategies LLC, BNP Paribas Arbitrage SA, UBS Asset Management Americas Inc., AQR Capital Management LLC, WINTON GROUP Ltd, and Rhenman & Partners Asset Management AB. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Corp /De/ Celgene, Habib J Dable, John D Quisel, Kevin F Mclaughlin, Sujay Kango, Terrence C Kearney, and Thomas A Mccourt.
View insider buying and selling activity for Acceleron Pharma
.

Which institutional investors are buying Acceleron Pharma stock?

XLRN stock was purchased by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, BlackRock Inc., First Trust Advisors LP, Handelsbanken Fonder AB, Alkeon Capital Management LLC, Candriam Luxembourg S.C.A., Great West Life Assurance Co. Can, and Charles Schwab Investment Management Inc.. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene, and Joseph S Zakrzewski.
View insider buying and selling activity for Acceleron Pharma
.

How do I buy shares of Acceleron Pharma?

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $114.40.

How big of a company is Acceleron Pharma?

Acceleron Pharma has a market capitalization of $6.89 billion and generates $73.99 million in revenue each year. The biopharmaceutical company earns $-124,860,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis. Acceleron Pharma employs 237 workers across the globe.

What is Acceleron Pharma's official website?

The official website for Acceleron Pharma is www.acceleronpharma.com.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.